Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 20

1.

[Aspirin in primary prevention of cardiovascular diseases: how to balance risks and benefits].

De Caterina R, Orlando D, Berti V, Coccheri S.

G Ital Cardiol (Rome). 2012 Jul-Aug;13(7-8):494-502. doi: 10.1714/1114.12245. Review. Italian.

PMID:
22781376
2.

Aspirin for the primary prevention of cardiovascular diseases.

Tagliabue L, Dipaola F, Perego F, Podda GM; Gruppo di Autoformazione Metodologica (GrAM)..

Intern Emerg Med. 2012 Aug;7(4):375-9. doi: 10.1007/s11739-012-0791-z. Epub 2012 Jun 6. No abstract available.

PMID:
22669555
3.

Platelets, endothelium, and circulating microRNA-126 as a prognostic biomarker in cardiovascular diseases: per aspirin ad astra.

Cavarretta E, Chiariello GA, Condorelli G.

Eur Heart J. 2013 Nov;34(44):3400-2. doi: 10.1093/eurheartj/eht032. Epub 2013 Feb 7. No abstract available.

PMID:
23391580
4.

Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases.

Serrano P, Lanas A, Arroyo MT, Ferreira IJ.

Aliment Pharmacol Ther. 2002 Nov;16(11):1945-53.

5.

Primary prevention for cardiovascular diseases: can statins replace aspirin?

Abdul Hadi M, Ming LC, Awaisu A.

Med Princ Pract. 2011;20(6):584. doi: 10.1159/000330033. Epub 2011 Oct 4. No abstract available.

6.
7.

[Aspirin for primary prevention of cardiovascular diseases--lessons from recent studies].

Balmor GR, Shoenfeld Y.

Harefuah. 2010 Nov;149(11):712-4, 749, 748. Hebrew.

PMID:
21250412
8.

[Aspirin for the primary prevention of cardiovascular diseases in diabetic patients. A review of currently available tests].

Maciá Bobes C, Ronzón Fernández A, Fernández García E.

Rev Esp Salud Publica. 2006 Nov-Dec;80(6):613-20. Review. Spanish.

10.
11.

Would it be more beneficial to take aspirin in the evening for prevention of cardiovascular diseases?

Kriszbacher I, Koppán M, Bódis J.

J Vasc Surg. 2005 Feb;41(2):375. No abstract available.

12.

The role of aspirin in cardiovascular diseases--forgotten benefits?

Williams A, Hennekens CH.

Expert Opin Pharmacother. 2004 Jan;5(1):109-15. Review.

PMID:
14680440
13.

[Prevention of cardiovascular diseases in type 2 diabetes with aspirin].

Duly-Bouhanick B, Menard S, Hadjadj S, Soares-Barbosa S, Plun-Favreau J, Guilloteau G.

Presse Med. 2001 Jan 20;30(2):87-91. Review. French.

PMID:
11244821
14.

[Prevention of cardiovascular and degenerative diseases: I. Aspirin, statins, or vitamins?].

Martin-Du Pan RC.

Rev Med Suisse Romande. 2003 Mar;123(3):175-81. Review. French.

PMID:
15095704
15.

[The modern view on the use of aspirin for the primary prophylaxis of cardiovascular diseases in women].

Zakharov OV, Arablinskiĭ AV.

Klin Med (Mosk). 2006;84(11):10-5. Review. Russian.

PMID:
17243603
16.

[Primary prevention with aspirin for cardiovascular diseases in diabetic patients. What evidence supports the criteria of the ADA?].

Maciá Bobes C, Ronzón Fernández A, Fernández García E.

Aten Primaria. 2007 Mar;39(3):163-4. Spanish. No abstract available.

PMID:
17386212
17.

[Aspirin and primary prevention of cardiovascular diseases in the elderly].

Manríquez M, Vallano A.

Rev Esp Geriatr Gerontol. 2009 Nov-Dec;44(6):349-51. doi: 10.1016/j.regg.2009.06.001. Epub 2009 Sep 1. Spanish. No abstract available.

PMID:
19726108
18.

[Clinical trials meta-analysis doubting about the position of aspirin in primary prevention of the cardiovascular diseases].

Hu DY.

Zhonghua Nei Ke Za Zhi. 2009 Oct;48(10):805. Chinese. No abstract available.

PMID:
20079216
19.

[Aspirin for primary prevention of cardiovascular diseases].

Li XY.

Zhonghua Yi Xue Za Zhi. 2005 Apr 6;85(13):889-91. Chinese. No abstract available.

PMID:
16029526
20.

Aspirin treatment and risk of first incident cardiovascular diseases in patients with type 2 diabetes: an observational study from the Swedish National Diabetes Register.

Ekström N, Cederholm J, Zethelius B, Eliasson B, Fhärm E, Rolandsson O, Miftaraj M, Svensson AM, Gudbjörnsdottir S.

BMJ Open. 2013 Apr 20;3(4). pii: e002688. doi: 10.1136/bmjopen-2013-002688. Print 2013.

Supplemental Content

Support Center